Company news
Modus Therapeutics Holding Ab (OMXSTO:MODTX) news
Modus Therapeutics Holding Ab news releases on 6ix. Latest, May 26, 2026: Modus Therapeutics publishes interim report for Q1 2026
Press releases & updates
Modus Therapeutics publishes interim report for Q1 2026
May 26, 2026
Modus announces outcome of exercise of warrants of series TO 2026 and receives approximately SEK 9.5 million
April 27, 2026
Modus Therapeutics Holding AB (publ) publishes annual report for the financial year 2025
April 15, 2026
Modus Therapeutics publishes year-end report for 2025
February 25, 2026
Modus Therapeutics publishes Interim report for the third quarter 2025
November 26, 2025
Interim Report - January-September 2025
November 14, 2025
Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia
November 4, 2025
Modus Therapeutics receives regulatory approval for Part 2 of the Phase IIa study in CKD-with anemia
November 3, 2025
Neumirna Therapeutics Appoints Ellen K. Donnelly as Chief Executive Officer
September 18, 2025
Modus resolves on compensation issue to guarantors in completed rights issue
September 2, 2025
Karolinska Development's portfolio company Modus Therapeutics raises SEK 28.3 million in oversubscribed unit issue
August 28, 2025
Modus Therapeutics raises approximately SEK 28.3 million in oversubscribed unit issue
August 27, 2025
Modus Therapeutics Holding AB Publishes Prospectus in Connection with the Upcoming Rights Issue of Units
August 11, 2025
Modus Therapeutics publishes Interim report for the second quarter 2025
August 7, 2025
Karolinska Development's portfolio company Modus Therapeutics completes enrollment in part 1 of its phase 2a study with sevuparin
July 14, 2025
Karolinska Development's portfolio company Modus Therapeutics carries out a fully secured rights issue of SEK 28.3 million
June 27, 2025